This has completed phase 2 and looks promising - The study, “Repeated 5-day cycles of low dose aldesleukin in amyotrophic lateral sclerosis (IMODALS): A phase 2a randomised, double-blind, placebo-controlled trial,” was published in the journal Lancet EBioMedicine. It was conducted by a consortium of clinical and laboratory scientists from France, U.K., Italy, and Sweden. More info from https://alsnewstoday.com/2020/07/17/...aign=OneSignal
- Welcome to the MND Association Forum.
If this is your first visit, be sure to check out the Forum Guidelines. You will need to Register before you can post. All registrations are manually approved by the Forum Admin team to try and help prevent spam so there may be a slight delay between registering and being able to post.
To start viewing posts, select the section of the forum that you want to visit from the selection below.
Comment